Monash antibiotic discovery to be developed in China

A new polymyxin antibiotic targeting Gram-negative ‘superbug’ infections, developed by scientists at the Monash Institute of Pharmaceutical Sciences and the Monash Biomedicine Discovery Institute (BDI), Monash University, will undergo development and commercialisation in China by Brii Biosciences. This partnership includes a polymyxin drug candidate, developed by Professor Jian Li, which Qpex in-licensed from Monash University earlier this year. Read more.